ArticleJournal of molecular histology2025
Huangqi Guizhi Wuwu Decoction inhibits ferroptosis to improve cyclophosphamide induced immunosuppression through regulation of arachidonic acid metabolism.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Huangqi Guizhi Wuwu Decoction (HGWD) has shown laboratory efficacy in autoimmune diseases, however its effectiveness and mechanism in addressing the decline of immune function remain unclear. We first established a cyclophosphamide-induced mouse model of immunosuppression and evaluated various immune indicators to determine the efficacy of HGWD in improving the immune function of CTX-immunosuppressed mice. Next, we conducted serum non-targeted metabolomics analysis to investigate HGWD’s effects on serum differential metabolites and used KEGG pathway enrichment analysis to identify the key pathways through which HGWD improves immune function. Finally, we validated HGWD’s impact on arachidonic acid (AA) metabolism and ferroptosis. HGWD treatment significantly improves the number of immune cells, ameliorates thymus and spleen tissue pathology, and restores the immune function. Non-targeted metabolomics analysis indicated that AA metabolism was a common pathway among the control group, CTX group, and H-HGWD group. HGWD intervention resulted in downregulation of serum levels of 15(S)-HpETE, 16(R)-HETE, Prostaglandin H2, and Prostaglandin G2 in CTX-immunosuppressed mice, while upregulating the level of 12(S)-HETE. RT-qPCR and Western blot analyses revealed that HGWD intervention significantly downregulated the expressions of ALOX15, CYP2C, ALOX12, and COX1, while upregulating GPX4 expression. Furthermore, HGWD intervention reduced TUNEL-positive expression in spleen tissue, improved levels of ferroptosis-related factors (total iron, MDA, 4-HNE, GSH/GSSG), and modulated expressions of ferroptosis-related proteins (FTL, FTH, TRF, and ACSL4). Our research has confirmed the significant potential of HGWD in improving the immune function of CTX-immunosuppressed mice. Specifically, HGWD may improve immune function by regulating AA metabolism to inhibit ferroptosis.
Indexed as
Identifiers
40892292What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.